U.S. Healthcare Services Stock News

Honeywell International (HON) is back in focus as investors weigh strong recent momentum in its Aerospace Technologies segment, alongside the upcoming January 29 earnings report, which ties current share performance closely to near term demand trends. See our latest analysis for Honeywell International. At a share price of $205.24, Honeywell’s recent 1 month share price return of 7.92% and 7.59% three year total shareholder return suggest momentum has been improving as investors react to...

Starbucks recently regained inclusion in Walt Disney World’s 2026 Disney Dining Plan, restoring its coffeehouses at key parks such as EPCOT’s Connections Café and Magic Kingdom’s Main Street Bakery to the program and potentially enhancing guest traffic and on-site spending. This renewed Disney partnership underscores how powerful venue tie-ins can reinforce Starbucks’ role as an everyday treat woven into major leisure experiences. We’ll now examine how the revived Disney Dining Plan access,...

Wondering whether Tilray Brands at around US$9.13 is priced for a rebound or more pain? This article walks you through what that price might actually imply about value. The stock has recently shown mixed momentum, with a 1.1% return over the last 7 days and 12.9% over the last 30 days, while still sitting on a 6.1% decline year to date and a 33.4% decline over the past year. Recent coverage around Tilray Brands has focused on its position in the cannabis and consumer packaged goods space, as...

If you are wondering whether Archrock is fairly priced or offering value at its recent levels, you are in the right place. Archrock's share price recently closed at US$26.06, with returns of 0.2% over 7 days, 3.0% over 30 days, a 2.1% decline year to date, and gains of 6.3% over 1 year, 207.7% over 3 years and 230.9% over 5 years. These return figures give useful context for thinking about what investors have been willing to pay for the stock over different periods and how sentiment has...

If you are wondering whether Qorvo's share price gives you good value right now, this article focuses on what the numbers say rather than market hype. The stock closed at US$82.88, with a 1.9% decline over the last 7 days and a 7.0% decline over 30 days, even though the 1 year return sits at 13.4% and the 5 year return at a 54.9% decline. Recent coverage of Qorvo has highlighted its role in the broader semiconductor space and how sentiment around the sector can affect companies with similar...

Franklin Resources (BEN) is back in focus after reporting preliminary assets under management of US$1.68b for December 2025, supported by US$28b in long term net inflows and gains across equity, fixed income, and alternatives. See our latest analysis for Franklin Resources. At a share price of US$25.45, Franklin Resources has seen buying interest build recently, with a 7 day share price return of 6.53% and a 1 year total shareholder return of 36.19%, suggesting momentum has been improving as...

Analog Devices (ADI) moved higher as part of a broad semiconductor rally, with investors responding to growing enthusiasm around artificial intelligence and the possibility of more accommodative Federal Reserve policy supporting risk assets. See our latest analysis for Analog Devices. The recent move to a US$299.16 share price comes on top of a 32.77% 90 day share price return and a 37.95% 1 year total shareholder return, hinting at building momentum as AI enthusiasm meets a lower P/E and P/B...

Mueller Water Products (MWA) moved higher as investors rotated into defensive names following news of a large proposed government infrastructure and defense spending plan, with the stock gaining 3.5% in the afternoon session. See our latest analysis for Mueller Water Products. That 3.5% intraday move sits on top of a 4.95% 7 day share price return and a 4.43% year to date share price return, while the 1 year total shareholder return of 14.34% and 3 year total shareholder return of 115.64%...

Amgen (AMGN) has just entered an exclusive license agreement with DISCO Pharmaceuticals, giving it global rights to develop cancer therapies based on DISCO's cell surface proteomics platform. This move directly targets new oncology opportunities. See our latest analysis for Amgen. That DISCO Pharmaceuticals agreement comes on top of a busy few days for Amgen, including the up to $840 million Dark Blue Therapeutics cancer deal and an upgrade from UBS. The shares trade at $330.11 after a 5.18%...

Helen of Troy's Latest Numbers Set a Tough Backdrop Helen of Troy (HELE) has just posted another tough quarter, with Q2 2026 revenue at US$431.8 million and a basic EPS loss of US$13.44, alongside trailing twelve month revenue of US$1.8 billion and a basic EPS loss of US$28.77. Over recent periods, the company has seen quarterly revenue move between US$371.7 million and US$530.7 million, while basic EPS has swung from profits of around US$2.22 per share to losses of US$19.65 and US$13.44 per...

TD SYNNEX (SNX) has reported fresh FY 2025 numbers with Q3 revenue of about US$15.7b and basic EPS of US$2.76, set against trailing 12 month revenue of roughly US$61.0b and EPS of US$9.24. The company has seen quarterly revenue range from about US$14.5b to US$15.8b over the last six reported periods, while basic EPS has moved between US$1.67 and US$2.76 across the same timeframe. This gives investors a clear view of how earnings are tracking alongside a very large top line. With trailing net...

Earlier this week, Figure Technology Solutions, Inc. (NASDAQ: FIGR) hit a fresh all-time high as investors reacted to growing expectations of Federal Reserve interest-rate cuts that could support rate-sensitive lending activity. The news underscored how Figure’s business model is closely tied to movements in borrowing costs, particularly in mortgages, refinancing, and home equity lending. With this backdrop of anticipated rate cuts potentially aiding residential lending demand, we’ll examine...

Acuity Brands (AYI) has just opened Q1 2026 earnings season with context of recent quarterly revenue of US$1.2b and basic EPS of US$3.71, alongside trailing twelve month EPS of US$12.85 on revenue of US$4.3b. Over the past few quarters, the company has seen revenue move from US$968.1m in Q3 2024 to US$1.2b in Q4 2025, while quarterly basic EPS has ranged from US$2.50 to US$3.86 across that stretch. This sets the backdrop for how you might frame the latest print. With trailing net profit...

Richardson Electronics (RELL) just posted its latest quarter with Q2 2026 revenue of US$54.6 million and basic EPS of US$0.13, while trailing 12 month figures sit at US$209.8 million of revenue and EPS of US$0.01. Over recent quarters the company has seen revenue move between US$47.4 million and US$54.6 million, with basic EPS ranging from a quarterly loss of US$0.14 to a profit of US$0.13. This feeds into a trailing year that includes one large US$2.8 million loss item and only a small net...

Abbott Laboratories (ABT) just introduced Libre Assist within its Libre app at CES 2026, using generative AI and continuous glucose data to give diabetes patients real time guidance on how upcoming meals might affect their glucose levels. See our latest analysis for Abbott Laboratories. The Libre Assist launch comes as Abbott’s share price sits at US$126.18, with a 30 day share price return of 4.07% and some recent volatility reflected in a 90 day share price return of a 4.82% decline, while...

Moog (MOG.A) is back on many investors’ screens after a series of earnings surprises over the last four quarters. This has aligned with stronger sentiment and fresh debate around what the stock is worth. See our latest analysis for Moog. Recent enthusiasm has also shown up in the trading data, with a 12.18% 30 day share price return and a 30.45% 1 year total shareholder return. This points to building momentum around Moog at the current US$262.98 share price. If Moog has caught your...

Globus Medical (GMED) is back in focus after management issued new guidance that points to fourth quarter 2025 sales of about US$823.2 million and full year 2025 revenue of roughly US$2.936b. See our latest analysis for Globus Medical. The guidance update has arrived after a strong run in the shares, with a 90-day share price return of 67.26% and a 1-year total shareholder return of 9.32%. This suggests that momentum has recently picked up from a more modest long term profile. If this kind of...

Applied Digital (APLD) reported Q2 2026 revenue of US$126.6 million with a basic EPS loss of US$0.11, alongside earnings from discontinued operations of US$12.1 million and net income excluding extra items showing a loss of US$31.2 million. Over the past three quarters, the company has seen revenue move from US$38.0 million in Q4 2025 to US$64.2 million in Q1 2026 and then to US$126.6 million in Q2 2026. Over the same period, basic EPS moved from a loss of US$0.12 in Q4 2025 to a loss of...

Earlier this week at CES 2026, Garmin unveiled its Unified Cabin 2026 automotive platform with an AI/LLM-based virtual assistant, expanded its Qualcomm-powered Nexus high-performance compute collaboration, and introduced new trucking camera and JL Audio AP Amplifier products for marine and off-road vehicles. Together, these launches highlight Garmin’s push deeper into software-rich automotive and connected audio systems, positioning its hardware as part of broader, integrated in-cabin and...

Simply Good Foods (SMPL) has just opened its 2026 financial year with Q1 results that cap a choppy run of quarterly earnings, moving from Basic EPS of US$0.41 and US$0.36 in Q3 and Q2 2025 to a loss of US$0.12 in Q4 2025, on quarterly revenue that moved between US$341.3 million and US$381.0 million over that 2025 span. Over the same period, trailing 12 month revenue ranged from about US$1.33 billion to US$1.46 billion, while trailing EPS moved between US$1.03 and US$1.47. Taken together, this...

Why Albertsons Companies Stock Is On Investors’ Radar Albertsons Companies (ACI) has drawn fresh attention after recent share price moves, with the stock closing at $16.63 as investors reassess its position in the competitive US food and drug retail sector. See our latest analysis for Albertsons Companies. The latest 3.4% 1 day share price return contrasts with weaker recent momentum, including a 3.5% 30 day share price return and a 13.8% 1 year total shareholder return. This suggests...

PACS Group recently attracted supportive analyst coverage highlighting its revenue growth, stronger internal controls after an audit, and a renewed focus on healthcare services expansion. At the same time, the company has reinforced its leadership with new Chief Compliance Officer and Chief Human Resources Officer appointments, underlining a stronger governance and culture framework. Next, we will examine how this combination of enhanced management oversight and analyst confidence shapes...

CBRE Group stock update CBRE Group (CBRE) has attracted fresh attention after recent share price moves, with the stock showing a 0.2% decline over the past day but gains over the past week and month. See our latest analysis for CBRE Group. The recent 7 day share price return of 3.2% and 30 day return of 6.4% sit within a broader picture where the year to date share price return is 3.6%. The 1 year total shareholder return of 27.9% and 5 year total shareholder return of 166.6% point to strong...

FDA clinical hold and new patent shift Erasca’s risk profile The key trigger for Erasca (ERAS) was the FDA’s partial clinical hold on its Phase 1 BOREALIS-1 trial for ERAS-4001, paired with fresh patent protection for its pan-RAS molecular glue ERAS-0015. See our latest analysis for Erasca. After a sharp pre-market drop on the clinical hold news, Erasca’s recent catalyst mix, including the ERAS-0015 patent and competitor data in pan-KRAS, has coincided with a 90-day share price return of...